Ademi LLP is investigating Organon (NASDAQ: TBRG) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Sun Pharma.
Organon stockholders will receive $14.00 per share in an all‑cash transaction with an enterprise valuation of $11.75 billion. Organon insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Organon by imposing a significant penalty if Organon accepts a competing bid. We are investigating the conduct of the Organon board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
Join this Action